Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127226181 | 12722618 | 1 | I | 20130316 | 20160823 | 20160907 | 20160907 | EXP | US-ROCHE-1827207 | ROCHE | 8.00 | YR | M | Y | 21.20000 | KG | 20160907 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127226181 | 12722618 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | (FREQUENCY AS PER PROTOCOL) | 125085 | 840 | MG | SOLUTION FOR INFUSION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127226181 | 12722618 | 1 | Medulloblastoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127226181 | 12722618 | DE |
| 127226181 | 12722618 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127226181 | 12722618 | Anaemia | |
| 127226181 | 12722618 | Death | |
| 127226181 | 12722618 | Lymphocyte count decreased | |
| 127226181 | 12722618 | Neutrophil count decreased | |
| 127226181 | 12722618 | Platelet count decreased | |
| 127226181 | 12722618 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127226181 | 12722618 | 1 | 20120507 | 20120618 | 0 |